Roxana S. Dronca, M.D.
Roxana S. Dronca, M.D., of Mayo Clinic in Rochester, Minn., is looking forward to translating innovative bench results into rationally developed clinical trials using personalized therapeutic strategies for patients with cancer.
"I want to make a difference in the care of patients with advanced melanoma and other incurable malignancies," says Dr. Dronca.
Dr. Dronca hopes to develop an innovative approach to cancer therapy using chemotherapy and immunotherapy agents administered in an individualized fashion and synchronized to predictable patient-specific endogenous anti-tumor immune dynamics. Dr. Dronca is studying the biology of sex-based differences in the outcome of malignant melanoma and identifying the impact of hormonal modulation on immunobiological interactions — driving the balance between tolerance and immune activation in patients with advanced cancers.
"I believe that elucidating the neuroendocrine modulation of immunity in melanoma will have applicability to other tumor types and is also likely to affect the care of women and men with other conditions modulated by inflammatory and immune responses," says Dr. Dronca.
Dr. Dronca says the strength of biomedical research is significantly enhanced when bright minds from diverse disciplines are involved.
"Mayo Clinic's unique patient-oriented multidisciplinary research environment and collegial collaboration of enthusiastic world-renowned experts makes this a perfect place for a breakthrough achievement in cancer treatment to happen," says Dr. Dronca.
- Alexey A. Leontovich, Ph.D., Biomedical Statistics and Informatics
- Larry R. Pease, Ph.D., Immunology
- Lynne T. Shuster, M.D., General Internal Medicine
- Franklyn G. Prendergast, M.D., Ph.D., Pharmacology
- Lynn C. Hartmann, M.D., Medical Oncology